GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
5 Phases
Drug Approvals
126
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
Clinical Trials
Distribution across different clinical trial phases (3330 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
- Conditions
- Influenza, Human
- Interventions
- Biological: Flu mRNA (Formulation B1)Biological: Flu mRNA (Formulation B3)Biological: Flu mRNA(Formulation A)Combination Product: Comparator 1Combination Product: Comparator 2Combination Product: Comparator 3
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 960
- Registration Number
- NCT07204964
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
- Conditions
- Bronchiectasis
- Interventions
- Drug: GSK3862995BDrug: Placebo
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 400
- Registration Number
- NCT07201051
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1196
- Registration Number
- NCT07177339
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT07168356
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT07150091
- Locations
- π°π·
GSK Investigational Site, Ulsan, South Korea
- Prev
- 1
- 2
- 3
- 4
- 5
- 713
- Next
News
Bioxodes Appoints Industry Veteran Philippe Monteyne as Chairman to Advance Breakthrough Stroke Therapy BIOX-101
Bioxodes has appointed Philippe Monteyne, MD, PhD, a former GSK and Sanofi executive with extensive neurological expertise, as chairman of its Board of Directors to guide development of breakthrough stroke candidate BIOX-101.
Sitryx Receives FDA Clearance for First-in-Class PKM2 Modulator SYX-5219 in Atopic Dermatitis
Sitryx Therapeutics received FDA clearance for its IND application for SYX-5219, a first-in-class oral PKM2 modulator targeting atopic dermatitis.
AnaptysBio Plans Corporate Split to Separate Royalty Assets from Drug Development Operations
AnaptysBio announced plans to separate into two independent public companies by year-end 2026, creating distinct investment opportunities for royalty management and drug development operations.
Cue Biopharma Appoints Dr. Usman Azam as CEO, Pivots to Autoimmune Disease Focus with CUE-401
Cue Biopharma has appointed Dr. Usman Azam as President and CEO, effective September 29, 2025, bringing over 25 years of drug development experience including CAR-T cell therapy leadership at Novartis.
GSK CEO Emma Walmsley to Step Down, Luke Miels Named Successor
Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down as GSK CEO on December 31 after more than eight years at the helm.
Pi Health Partners with GSK to Accelerate Phase 2 Oncology Trial Using AI-Powered Platform
Pi Health has entered a Master Clinical Services Outsourcing Agreement with GSK to provide fully outsourced clinical research services for a global Phase 2 oncology clinical trial.
FDA Breaks Precedent with Literature-Based Approval for Leucovorin in Cerebral Folate Deficiency
The FDA is initiating approval of leucovorin calcium tablets for cerebral folate deficiency based on systematic literature analysis rather than traditional clinical trials, marking a departure from the agency's standard evidence requirements.
Transpire Bio Achieves FDA Filing Acceptance for Generic Breo Ellipta, Positioning for Market Exclusivity
Transpire Bio's abbreviated new drug application (ANDA) for a generic version of Breo Ellipta has been accepted for filing by the U.S. FDA, marking a significant milestone for the company's complex generic franchise.
GSK to Submit Label Update for Leucovorin Following FDA Request for Cerebral Folate Deficiency Treatment
GSK will submit a supplemental New Drug Application to update Wellcovorin (leucovorin) labeling to include cerebral folate deficiency treatment at FDA's request as part of the agency's initiative to repurpose older medications.
CDC Advisory Panel Votes to Limit Combined MMRV Vaccine Use in Young Children Due to Seizure Risk
The CDC's Advisory Committee on Immunization Practices voted 8-3 to recommend against using Merck's combined MMRV vaccine for first doses in children age 4 and younger, citing double the rate of febrile seizures compared to separate shots.